

Place: Noida
Dated: 24 May 2019

AstraZeneca Pharma India Limited

CIN: L24231KA1979PLC003563
 Regd. Office: Block N1, 12th Floor, Manyata Embassy Business Park,
 Rachenahalli, Outer Ring Road, Bangalore - 560 045.
 Tel.: +91 80 6774 8000. Web: www.astrazeneca.com/india

Statement of financial results for the quarter and year ended 31 March 2019

Sl. No.	Particulars	Rs. in lakhs (except for earnings per share data)			
		3 months ended 31 March 2019	Corresponding 3 months ended in the previous year 31 March 2018	Year ended 31 March 2019	Previous year ended 31 March 2018
		Refer Note 3	Refer Note 3	Audited	Audited
1	Total income from operations	19,631.49	15,306.48	74,457.95	58,423.68
2	Net profit / (loss) for the period from ordinary activities before tax	847.32	1,405.68	7,266.35	4,380.01
3	Net profit / (loss) for the period from ordinary activities after tax	982.38	322.14	5,444.07	2,591.48
4	Total comprehensive income for the period after tax	1,132.86	(188.48)	5,384.02	2,363.49
5	Equity Share Capital	500.00	500.00	500.00	500.00
6	Reserves (excluding revaluation reserves as per balance sheet)	-	-	29,580.50	24,193.18
7	Basic and diluted earnings per share (of Rs 2 each)	3.93	1.29	21.78	10.37

Note:

- The above is an extract of the detailed format of Quarterly and Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Yearly Financial Results is available on the Stock Exchange websites. (www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).
- The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The figures for the quarter ended 31 March, 2019 and 31 March, 2018 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial year which were subjected to review by the statutory auditors.

By Order of the Board of Directors
 For AstraZeneca Pharma India Limited
 Gagandeep Singh Bedi
 Managing Director

Place: Bengaluru
 Date: 24 May, 2019



ROSSELL INDIA LIMITED

Regd. Office : Jindal Towers, Block 'B', 4th Floor,
 21/1A/3, Darga Road, Kolkata-700 017

CIN : L01132WB1994PLC063513 Website : www.rossellindia.com
 E-mail : corporate@rosselltea.com

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2019

Sl. No.	Particulars	Rs. in lakhs						
		Standalone (Audited)				Consolidated (Audited)		
		Three months ended 31.03.2019	Three months ended 31.12.2018	Three months ended 31.03.2018	Year ended 31.03.2019	Year ended 31.03.2018	Year ended (Note 3 below) 31.03.2019	Year ended 31.03.2018
1.	Total Income from Operations	4,728	8,354	3,740	24,868	19,852	-	19,852
2.	Net Profit (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(1,760)	267	(1,997)	50	(161)	-	(161)
3.	Net Profit (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(1,771)	267	(1,997)	39	(161)	-	(161)
4.	Net Profit (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(1,514)	224	(1,472)	57	24	-	24
5.	Total Comprehensive Income for the period [Comprising Profit (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1,498)	216	(1,425)	50	(5)	-	(5)
6.	Equity Share Capital	734	734	734	734	734	-	734
7.	Reserves (excluding Revaluation Reserve)	-	-	-	16,187	16,135	-	16,124
8.	Earnings Per Share (of Rs. 2 each) (for continuing and discontinued operations) -							
	- Basic (Rs.)	(4.13)	0.61	(4.01)	0.16	0.07	-	0.07
	- Diluted (Rs.)	(4.13)	0.61	(4.01)	0.16	0.07	-	0.07

Notes :

HEALTHCARE GLOBAL ENTERPRISES LIMITED

Regd. Off.: HCG Towers, No. 8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027
 CIN: L15200KA1998PLC023489
 Phone: +91 80 4660 7700, Fax: +91 80 4660 7749
 Email: investors@hcgoncology.com | Website: www.hcgl.com



EXTRACT OF THE CONSOLIDATED & STANDALONE RESULTS FOR THE QUARTER & YEAR ENDED 31st MARCH 2019

Particulars	Consolidated				Standalone			
	(Amount in Rs. Lakhs)							
	Quarter ended 31 st March 2019	Quarter ended 31 st March 2018	Full year ended 31 st March 2019	Full year ended 31 st March 2018	Quarter ended 31 st March 2019	Quarter ended 31 st March 2018	Full year ended 31 st March 2019	Full year ended 31 st March 2018
	Refer note 3		Audited		Refer note 3		Audited	
Total income from operations (net.)	26,115.00	22,488.00	98,608.00	84,349.00	17,274.00	15,696.00	65,398.00	60,280.00
Net profit/(loss) for the period (before tax and exceptional items)	(818.00)	(224.00)	(3,338.00)	1,641.00	610.00	908.00	1,257.00	3,394.00
Net profit/(loss) for the period (after tax and exceptional items)	(1,088.00)	(16.00)	(3,088.00)	1,641.00	303.00	765.50	725.00	2,490.00
Net Profit/(loss) for the period attributable to equity share holders of the company	(872.00)	259.00	(2,480.00)	2,052.00	303.00	765.50	725.00	2,490.00
Total comprehensive income for the period (Comprising net profit and other comprehensive income after tax)	(854.00)	241.00	(2,767.00)	2,034.00	295.00	746.00	313.00	2,470.00
Equity share capital	8,792.00	8,690.00	8,792.00	8,690.00	8,792.00	8,690.00	8,792.00	8,690.00
Earnings per share (of Rs.10 each) in Rs. Basic:	(0.99)	(0.30)	(2.82)	2.38	0.35	0.88	0.83	2.89
Earnings per share (of Rs.10 each) in Rs. Diluted:	(0.99)	(0.30)	(2.82)	2.38	0.35	0.88	0.82	2.89

Notes:

- The above results were reviewed by the audit committee and approved by the board of directors at their meeting held on 23 May 2019.
- The above Statement of Consolidated & Standalone Financial Results are based on respective Consolidated & Standalone financial statements, prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended, read with relevant rules issued thereunder in terms of the SEBI LODR, as modified by Circular No CIR/CFD/FAC/62/2016 dated July 6, 2016.
- The report of the statutory auditor is unqualified. The figures for the quarters ended 31 March 2019 and 31 March 2018 are the balancing figures between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review by the statutory auditor of the Company.
- The above results are an extract of the detailed format of quarterly and year ended results filed with BSE Ltd and National Stock Exchange of India Ltd as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the results are available on the websites of respective Stock Exchanges and the Company - https://hcgl.com/investors.
- The statement of category wise utilisation of net proceeds from Initial Public Offer is:

Category wise utilisation of net Proceeds from Initial Public Offer	Amount proposed to be utilised	Amount proposed to be utilised after reallocation	Actual Utilisation upto 31 st March, 2019
Purchase of medical equipment	4,220.00	258	258
Investment in IT software, services and hardware	3,019.00	2,981.00	2,981.00
Pre-payment of debt	14,704.00	14,704.00	14,704.00
General Corporate Purposes *	1,977.00	5,977.00	5,977.00
Total	23,920.00	23,920.00	23,920.00

(i) Rs. 3,962 lakhs from purchase of medical equipment and Rs. 38 lakhs from investment in IT software, services and hardware has been reallocated to General corporate purpose usage, as allowed by the 'Objects of the offer' section in the Prospectus of the Company for the Initial Public Offer.

* Includes Rs. 1,000 lakhs ear-marked for meeting payment commitments with regard to a contract for supply of IT softwares.

6. At the Board meeting held on 23 May 2019, the Board of Directors of the Company has approved the proposal for issuance of 710,526 equity shares of Rs. 10 per share at a price of Rs.285 per share (inclusive of face value of Rs.10 per share), on Preferential Allotment basis, to Dr. Gee Varghese ("Investor"), subject to the approval of the shareholders of the Company in the proposed Extra Ordinary General Meeting.

Date: May 23, 2019
 Place: Bengaluru

For HealthCare Global Enterprises Limited
 Dr. B. S. Ajakumar
 Chairman & CEO



AMBER ENTERPRISES INDIA LIMITED

Registered Office: C-1, Phase - II, Focal Point, Rajpura Town - 140 401, Punjab
 Corporate Office: Universal Trade Tower, 1st Floor, Sector -49, Sohna Road, Gurgaon - 122 018, Haryana
 E-mail: info@ambergroupindia.com; Website: www.ambergroupindia.com
 Tel: +91 124 3923000; Fax: +91 124 3923016, 17; CIN: L28910PB1990PLC010265

29%
 ↑
 CONSOLIDATED REVENUE

16%
 ↑
 EBIDTA

52%
 ↑
 PAT

Extract of Audited Financial Results for the quarter and year ended 31 March, 2019

(₹ in lakh except for per share data)